vs
CoStar Group（CSGP）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
CoStar Group的季度营收约是ICU MEDICAL INC的1.7倍（$899.9M vs $540.7M），CoStar Group净利率更高（5.2% vs -2.9%，领先8.1%），CoStar Group同比增速更快（26.9% vs -14.1%），CoStar Group自由现金流更多（$101.3M vs $36.0M），过去两年CoStar Group的营收复合增速更高（17.1% vs -2.3%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
CSGP vs ICUI — 直观对比
营收规模更大
CSGP
是对方的1.7倍
$540.7M
营收增速更快
CSGP
高出41.0%
-14.1%
净利率更高
CSGP
高出8.1%
-2.9%
自由现金流更多
CSGP
多$65.3M
$36.0M
两年增速更快
CSGP
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $540.7M |
| 净利润 | $46.5M | $-15.7M |
| 毛利率 | 78.6% | 37.5% |
| 营业利润率 | 5.5% | 1.0% |
| 净利率 | 5.2% | -2.9% |
| 营收同比 | 26.9% | -14.1% |
| 净利润同比 | -22.2% | 34.0% |
| 每股收益（稀释后） | $0.12 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPICUI
| Q4 25 | $899.9M | $540.7M | ||
| Q3 25 | $833.6M | $537.0M | ||
| Q2 25 | $781.3M | $548.9M | ||
| Q1 25 | $732.2M | $604.7M | ||
| Q4 24 | $709.4M | $629.8M | ||
| Q3 24 | $692.6M | $589.1M | ||
| Q2 24 | $677.8M | $596.5M | ||
| Q1 24 | $656.4M | $566.7M |
净利润CSGPICUI
| Q4 25 | $46.5M | $-15.7M | ||
| Q3 25 | $-30.9M | $-3.4M | ||
| Q2 25 | $6.2M | $35.3M | ||
| Q1 25 | $-14.8M | $-15.5M | ||
| Q4 24 | $59.8M | $-23.8M | ||
| Q3 24 | $53.0M | $-33.0M | ||
| Q2 24 | $19.2M | $-21.4M | ||
| Q1 24 | $6.7M | $-39.5M |
毛利率CSGPICUI
| Q4 25 | 78.6% | 37.5% | ||
| Q3 25 | 79.3% | 37.4% | ||
| Q2 25 | 78.5% | 37.9% | ||
| Q1 25 | 79.1% | 34.7% | ||
| Q4 24 | 80.1% | 36.1% | ||
| Q3 24 | 79.7% | 34.8% | ||
| Q2 24 | 80.0% | 34.8% | ||
| Q1 24 | 78.5% | 32.7% |
营业利润率CSGPICUI
| Q4 25 | 5.5% | 1.0% | ||
| Q3 25 | -6.1% | 2.6% | ||
| Q2 25 | -3.5% | 1.9% | ||
| Q1 25 | -5.8% | 2.1% | ||
| Q4 24 | 5.6% | 6.0% | ||
| Q3 24 | 3.4% | 1.4% | ||
| Q2 24 | -2.4% | 1.3% | ||
| Q1 24 | -6.5% | -1.9% |
净利率CSGPICUI
| Q4 25 | 5.2% | -2.9% | ||
| Q3 25 | -3.7% | -0.6% | ||
| Q2 25 | 0.8% | 6.4% | ||
| Q1 25 | -2.0% | -2.6% | ||
| Q4 24 | 8.4% | -3.8% | ||
| Q3 24 | 7.7% | -5.6% | ||
| Q2 24 | 2.8% | -3.6% | ||
| Q1 24 | 1.0% | -7.0% |
每股收益（稀释后）CSGPICUI
| Q4 25 | $0.12 | $-0.63 | ||
| Q3 25 | $-0.07 | $-0.14 | ||
| Q2 25 | $0.01 | $1.43 | ||
| Q1 25 | $-0.04 | $-0.63 | ||
| Q4 24 | $0.14 | $-0.97 | ||
| Q3 24 | $0.13 | $-1.35 | ||
| Q2 24 | $0.05 | $-0.88 | ||
| Q1 24 | $0.02 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | — |
| 总债务越低越好 | $140.0M | — |
| 股东权益账面价值 | $8.3B | $2.1B |
| 总资产 | $10.5B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGPICUI
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $3.6B | — | ||
| Q1 25 | $3.7B | — | ||
| Q4 24 | $4.7B | $308.6M | ||
| Q3 24 | — | $312.5M | ||
| Q2 24 | — | $302.6M | ||
| Q1 24 | — | $251.4M |
总债务CSGPICUI
| Q4 25 | $140.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
股东权益CSGPICUI
| Q4 25 | $8.3B | $2.1B | ||
| Q3 25 | $8.6B | $2.1B | ||
| Q2 25 | $8.6B | $2.1B | ||
| Q1 25 | $8.6B | $2.0B | ||
| Q4 24 | $7.6B | $2.0B | ||
| Q3 24 | $7.5B | $2.0B | ||
| Q2 24 | $7.4B | $2.0B | ||
| Q1 24 | $7.3B | $2.1B |
总资产CSGPICUI
| Q4 25 | $10.5B | $4.1B | ||
| Q3 25 | $10.8B | $4.1B | ||
| Q2 25 | $10.5B | $4.1B | ||
| Q1 25 | $10.4B | $4.2B | ||
| Q4 24 | $9.3B | $4.2B | ||
| Q3 24 | $9.1B | $4.3B | ||
| Q2 24 | $9.1B | $4.3B | ||
| Q1 24 | $9.0B | $4.3B |
负债/权益比CSGPICUI
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | $36.0M |
| 自由现金流率自由现金流/营收 | 11.3% | 6.6% |
| 资本支出强度资本支出/营收 | 6.8% | 4.6% |
| 现金转化率经营现金流/净利润 | 3.49× | — |
| 过去12个月自由现金流最近4个季度 | $123.0M | $91.8M |
8季度趋势，按日历期对齐
经营现金流CSGPICUI
| Q4 25 | $162.1M | $60.6M | ||
| Q3 25 | $68.2M | $56.7M | ||
| Q2 25 | $146.5M | $11.2M | ||
| Q1 25 | $53.2M | $51.3M | ||
| Q4 24 | $94.6M | $40.2M | ||
| Q3 24 | $100.3M | $36.1M | ||
| Q2 24 | $58.1M | $82.0M | ||
| Q1 24 | $139.6M | $45.8M |
自由现金流CSGPICUI
| Q4 25 | $101.3M | $36.0M | ||
| Q3 25 | $-5.5M | $27.6M | ||
| Q2 25 | $27.7M | $-8.5M | ||
| Q1 25 | $-500.0K | $36.7M | ||
| Q4 24 | $25.2M | $16.1M | ||
| Q3 24 | $40.2M | $16.2M | ||
| Q2 24 | $-14.7M | $62.5M | ||
| Q1 24 | $-237.1M | $29.9M |
自由现金流率CSGPICUI
| Q4 25 | 11.3% | 6.6% | ||
| Q3 25 | -0.7% | 5.1% | ||
| Q2 25 | 3.5% | -1.5% | ||
| Q1 25 | -0.1% | 6.1% | ||
| Q4 24 | 3.6% | 2.6% | ||
| Q3 24 | 5.8% | 2.7% | ||
| Q2 24 | -2.2% | 10.5% | ||
| Q1 24 | -36.1% | 5.3% |
资本支出强度CSGPICUI
| Q4 25 | 6.8% | 4.6% | ||
| Q3 25 | 8.8% | 5.4% | ||
| Q2 25 | 15.2% | 3.6% | ||
| Q1 25 | 7.3% | 2.4% | ||
| Q4 24 | 9.8% | 3.8% | ||
| Q3 24 | 8.7% | 3.4% | ||
| Q2 24 | 10.7% | 3.3% | ||
| Q1 24 | 57.4% | 2.8% |
现金转化率CSGPICUI
| Q4 25 | 3.49× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 23.63× | 0.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.58× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 20.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
